Kiniksa Pharmaceuticals International (KNSA) Competitors

$77.17 -2.16 (-2.72%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$77.17 +0.00 (+0.00%)

As of 09/18/2026 07:30 PM Eastern

KNSA vs. UTHR, GMAB, ASND, EXEL, and BBIO

Should you buy Kiniksa Pharmaceuticals International stock or one of its competitors? Kiniksa Pharmaceuticals International's main competitors and comparable companies include United Therapeutics (UTHR), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Exelixis (EXEL), and BridgeBio Pharma (BBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kiniksa Pharmaceuticals International compare to United Therapeutics?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, United Therapeutics had 23 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 23 mentions for United Therapeutics and 0 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat United Therapeutics' score of 0.65 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Overall Sentiment
Kiniksa Pharmaceuticals International	Positive
United Therapeutics	Positive

United Therapeutics has higher revenue and earnings than Kiniksa Pharmaceuticals International. United Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	8.89	$59.01M	$0.97	79.56
United Therapeutics	$3.18B	6.67	$1.33B	$27.95	17.70

United Therapeutics has a net margin of 41.56% compared to Kiniksa Pharmaceuticals International's net margin of 9.59%. United Therapeutics' return on equity of 20.18% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
United Therapeutics	41.56%	20.18%	17.98%

Kiniksa Pharmaceuticals International currently has a consensus target price of $87.38, indicating a potential upside of 13.23%. United Therapeutics has a consensus target price of $646.00, indicating a potential upside of 30.60%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Kiniksa Pharmaceuticals International has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Summary

United Therapeutics beats Kiniksa Pharmaceuticals International on 12 of the 16 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

In the previous week, Genmab A/S had 12 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 12 mentions for Genmab A/S and 0 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat Genmab A/S's score of 0.64 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Overall Sentiment
Genmab A/S	Positive
Kiniksa Pharmaceuticals International	Positive

Genmab A/S currently has a consensus price target of $39.50, indicating a potential upside of 13.70%. Kiniksa Pharmaceuticals International has a consensus price target of $87.38, indicating a potential upside of 13.23%. Given Genmab A/S's stronger consensus rating and higher possible upside, research analysts clearly believe Genmab A/S is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Kiniksa Pharmaceuticals International. Genmab A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.83	$963M	$1.27	27.35
Kiniksa Pharmaceuticals International	$677.56M	8.89	$59.01M	$0.97	79.56

Genmab A/S has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Genmab A/S has a net margin of 19.08% compared to Kiniksa Pharmaceuticals International's net margin of 9.59%. Genmab A/S's return on equity of 14.89% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Summary

Genmab A/S beats Kiniksa Pharmaceuticals International on 11 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Ascendis Pharma A/S has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Ascendis Pharma A/S presently has a consensus target price of $310.75, suggesting a potential upside of 31.27%. Kiniksa Pharmaceuticals International has a consensus target price of $87.38, suggesting a potential upside of 13.23%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ascendis Pharma A/S is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Ascendis Pharma A/S has a net margin of 70.99% compared to Kiniksa Pharmaceuticals International's net margin of 9.59%. Ascendis Pharma A/S's return on equity of 32.54% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Kiniksa Pharmaceuticals International has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.13	-$258M	$12.89	18.36
Kiniksa Pharmaceuticals International	$677.56M	8.89	$59.01M	$0.97	79.56

In the previous week, Ascendis Pharma A/S had 23 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 23 mentions for Ascendis Pharma A/S and 0 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat Ascendis Pharma A/S's score of 0.68 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Overall Sentiment
Ascendis Pharma A/S	Positive
Kiniksa Pharmaceuticals International	Positive

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Kiniksa Pharmaceuticals International on 11 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Exelixis?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Kiniksa Pharmaceuticals International has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Exelixis has higher revenue and earnings than Kiniksa Pharmaceuticals International. Exelixis is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	8.89	$59.01M	$0.97	79.56
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.35

Exelixis has a net margin of 35.33% compared to Kiniksa Pharmaceuticals International's net margin of 9.59%. Exelixis' return on equity of 42.17% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Exelixis	35.33%	42.17%	31.76%

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Exelixis had 15 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 15 mentions for Exelixis and 0 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat Exelixis' score of 0.44 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Overall Sentiment
Kiniksa Pharmaceuticals International	Positive
Exelixis	Neutral

Kiniksa Pharmaceuticals International presently has a consensus price target of $87.38, indicating a potential upside of 13.23%. Exelixis has a consensus price target of $50.29, indicating a potential downside of 13.84%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher possible upside, analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

Exelixis beats Kiniksa Pharmaceuticals International on 10 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to BridgeBio Pharma's net margin of -97.03%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

BridgeBio Pharma currently has a consensus target price of $102.61, indicating a potential upside of 54.05%. Kiniksa Pharmaceuticals International has a consensus target price of $87.38, indicating a potential upside of 13.23%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, BridgeBio Pharma had 8 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 8 mentions for BridgeBio Pharma and 0 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat BridgeBio Pharma's score of 0.87 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Overall Sentiment
BridgeBio Pharma	Positive
Kiniksa Pharmaceuticals International	Positive

BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.94	-$724.93M	-$3.57	N/A
Kiniksa Pharmaceuticals International	$677.56M	8.89	$59.01M	$0.97	79.56

Summary

Kiniksa Pharmaceuticals International beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

Get Kiniksa Pharmaceuticals International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KNSA vs. The Competition

Export

Metric	Kiniksa Pharmaceuticals International	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.19B	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	79.56	14.30	275.79	25.40
Price / Sales	8.89	1,415.50	695.58	114.44
Price / Cash	99.94	110.75	77.42	51.66
Price / Book	10.37	15.45	10.46	6.33
Net Income	$59.01M	-$22.86M	$3.49B	$358.33M
7 Day Performance	1.18%	-1.21%	0.59%	1.12%
1 Month Performance	-4.49%	-4.42%	-2.01%	-2.67%
1 Year Performance	117.87%	37.81%	18.09%	6.01%

Kiniksa Pharmaceuticals International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KNSA Kiniksa Pharmaceuticals International	3.9759 of 5 stars	$77.17 -2.7%	$87.38 +13.2%	+114.8%	$6.19B	$677.56M	79.56	366	Positive News High Trading Volume
UTHR United Therapeutics	4.2811 of 5 stars	$503.86 -0.6%	$646.00 +28.2%	+20.7%	$21.61B	$3.18B	18.03	1,400	Insider Trade
GMAB Genmab A/S	4.2675 of 5 stars	$32.23 -2.5%	$39.50 +22.6%	+23.9%	$20.10B	$3.72B	25.38	3,119	Analyst Revision
ASND Ascendis Pharma A/S	4.7241 of 5 stars	$261.23 +0.2%	$310.00 +18.7%	+18.7%	$16.30B	$814.57M	20.27	1,189	Analyst Downgrade
EXEL Exelixis	2.4963 of 5 stars	$57.43 -1.5%	$50.07 -12.8%	+44.3%	$14.23B	$2.32B	18.06	1,077	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KNSA) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. UTHR, GMAB, ASND, EXEL, and BBIO

How does Kiniksa Pharmaceuticals International compare to United Therapeutics?

Summary

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Summary

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Summary

How does Kiniksa Pharmaceuticals International compare to Exelixis?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. UTHR, GMAB, ASND, EXEL, and BBIO

How does Kiniksa Pharmaceuticals International compare to United Therapeutics?

Do insiders & institutionals believe in KNSA or UTHR?

Does the media favor KNSA or UTHR?

Which has stronger valuation & earnings, KNSA or UTHR?

Is KNSA or UTHR more profitable?

Do analysts recommend KNSA or UTHR?

Which has more volatility & risk, KNSA or UTHR?

Summary

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Does the media favor GMAB or KNSA?

Do analysts recommend GMAB or KNSA?

Do insiders & institutionals have more ownership in GMAB or KNSA?

Which has preferable valuation & earnings, GMAB or KNSA?

Which has more volatility & risk, GMAB or KNSA?

Is GMAB or KNSA more profitable?

Summary

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Which has more volatility & risk, ASND or KNSA?

Do analysts rate ASND or KNSA?

Is ASND or KNSA more profitable?

Which has better valuation and earnings, ASND or KNSA?

Does the media refer more to ASND or KNSA?

Do insiders and institutionals believe in ASND or KNSA?

Summary

How does Kiniksa Pharmaceuticals International compare to Exelixis?

Which has more risk & volatility, KNSA or EXEL?

Which has stronger earnings & valuation, KNSA or EXEL?

Is KNSA or EXEL more profitable?

Do insiders and institutionals have more ownership in KNSA or EXEL?

Does the media prefer KNSA or EXEL?

Do analysts rate KNSA or EXEL?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Is BBIO or KNSA more profitable?

Do analysts recommend BBIO or KNSA?

Does the media favor BBIO or KNSA?

Which has more risk and volatility, BBIO or KNSA?

Do insiders & institutionals have more ownership in BBIO or KNSA?

Which has preferable valuation & earnings, BBIO or KNSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools